Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06797999 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
A Phase 1 study of Metastatic Soft Tissue Sarcoma and Unresectable Soft Tissue Sarcoma, sponsored by Adcendo ApS.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 270
- Enrollment target
- 8
- Study locations
NCT06797999: Recruiting Phase 1 study of Metastatic Soft Tissue Sarcoma and Unresectable Soft Tissue Sarcoma, sponsored by Adcendo ApS.
NCT06797999 is a Phase 1 study of Metastatic Soft Tissue Sarcoma and Unresectable Soft Tissue Sarcoma that is actively recruiting participants, run by Adcendo ApS. The registered enrollment target is 270 participants, above the 118-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (129% higher). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06797999, a Phase 1 study of Metastatic Soft Tissue Sarcoma and Unresectable Soft Tissue Sarcoma, is actively recruiting participants, sponsored by Adcendo ApS.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 270 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
Primary Outcome
Measuring incidence of dose-limiting toxicities (DLTs)
Conditions Studied
Interventions
- BIOLOGICAL Antibody-drug conjugate (ADC)
Study Locations (8)
Other
- Universitair Ziekenhuis Leuven (UZ Leuven) - Campus Gasthuisberg - Leuven
- Centre Léon Bérard - Lyon
- Universitätsklinikum Essen West German Tumor Center - Essen
- Royal Marsden - London
Colorado
- University of Colorado Denver - Aurora
Florida
- University of Miami - Sylvester Comprehensive Cancer Center - Miami
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- University Of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2025-06-05 |
| Est. Completion | 2029-02-27 |
| Phase | Phase 1 |
What NCT06797999 shows while recruiting
NCT06797999 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, above the 118-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (129% higher).
The record links to 2 conditions, with Metastatic Soft Tissue Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Antibody-drug conjugate (ADC) is the first listed.
NCT06797999 lists 8 locations in 5 states (Other, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT06797999 about?
NCT06797999 is a clinical study titled "First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma". The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
What is the current status of trial NCT06797999?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 270 participants. The study started on 2025-06-05. Estimated completion is 2029-02-27.
What conditions does trial NCT06797999 study?
This clinical trial studies the following conditions: Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma.
What interventions are being tested in trial NCT06797999?
The interventions under investigation include: Antibody-drug conjugate (ADC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06797999?
This trial is sponsored by Adcendo ApS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06797999 being conducted?
This trial has 8 study locations across Colorado, Florida, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06797999's enrollment target sits among peer trials
270 2nd of 12 the highest of 12 other Metastatic Soft Tissue Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
RECRUITING · Phase 1
-
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
RECRUITING · Phase 1
-
T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
RECRUITING · Phase 1
-
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI